Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: JAMA Dermatol. 2013 Oct;149(10):1159–1165. doi: 10.1001/jamadermatol.2013.4207

Table 4.

Autoantibody Associations With Clinical Markers of Disease Activity and Severity in Morphea and its Subtypesa

Morphea Subtype/Autoantibody P Value
Limited Function BSAb mRSS Localized Scleroderma Skin
PGA
Severity Index Damage Index Activity Damage
Linear

 ANA NS .005 <.001 NS NS NS NS

 Anti-ssDNA .005 .01 NS NS NS NS NS

 Antihistone .006 NS NS NS NS NS NS

Total group of patients with morphea

 ANA NS NS <.001 NS NS NS NS

 Anti-ssDNA .03 NS NS NS NS NS NS

 Antihistone .007 NS NS NS NS NS NS

Abbreviations: ANA, antinuclear antibody; Anti-ssDNA, anti–single-stranded DNA; BSA, body surface area; mRSS, modified Rodnan Skin Score; NS, nonsignificant; PGA, Physician Global Assessment.

a

Only subtypes with statistically significant associations are shown. Generalized and plaque subtypes do not have any significant associations.

b

Extensive BSA is defined as having 3 or more body sites involved. For limited functionality and extensive BSA, 2-tailed χ2 tests with Yates correction were used, except when one of the expected values in the 2 × 2 table is less than 5, in which case the 2-tailed Fisher exact test was used. For mRSS, Localized Scleroderma Skin Severity Index, Localized Scleroderma Skin Damage Index, PGA of Activity, and PGA of Damage, Wilcoxon rank sum tests were used.